AZNAstraZenecaSigning up patients
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 255 (planned)
- Started
- Dec 29, 2023
- Main results expected
- Jan 6, 2028
- Fully finished
- Aug 10, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Frequency of DLTs
Measured over: Up to 28 days
Parts A & B: Safety Evaluation of AZD0486
Measured over: From signing of informed consent through data cutoff, up to 57 months
Parts B & C: Rate of CR within 3 cycles
Measured over: Up to three cycles of 28 days each
Part D: CR/CRh within 3 cycles
Measured over: Up to three cycles of 28 days each
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06137118 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC